Cardiovascular Systems Inc

Cardiovascular Systems — Investor Day (August 2022)

84 slides from Cardiovascular Systems's investor day presentation, Aug 3, 2022

  1. Slide 1: Capital Markets Day August 3, 2022

    Capital Markets Day August 3, 2022

  2. Slide 2: Welcome

    Welcome Jack Nielsen Vice President, Investor Relations & Corporate Communications

  3. Slide 3: Q4 FY22 Financial Results

    O04 FY22 Financial Results Dy) CARDIOVASCULAR

  4. Slide 4: Company Overview

    Capital Markets Day – August 3, 2022 Company Overview Scott R. Ward Chairman, President & Chief Executive Officer

  5. Slide 5: Forward Looking Statements Safe Harbor

    Forward Looking Statements Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  6. Slide 6: Financial Disclaimers

    Financial Disclaimers Financial Information This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI’s independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may l

  7. Slide 7: Regulatory Disclaimers

    Regulatory Disclaimers Product Availability Diamondback 360® Coronary Orbital Atherectomy System FDA-approved. Available for sale in the U.S. Diamondback 360® Peripheral Orbital Atherectomy System FDA-cleared. Available for sale in the U.S. Diamondback 360® Peripheral Orbital Atherectomy System – Ex

  8. Slide 8: Committed to getting people back to what matters

    Committed to getting people back to what matters

  9. Slide 9: Vision and Mission

    Vision To eliminate cardiovascular disease as a barrier to living a full life by providing awareness and access to quality treatment. Mission Saving Limbs. Saving Lives. Every Day. Patient Centric and Customer Focused Cardiovascular Systems, Inc. 700,000 Over 700,000 patients worldwide successfully

  10. Slide 10: CSI Board of Directors

    CSI Board of Directors Sachin H. Jain, M.D. Director since 2021 Scott R. Ward Chairman, President & CEO Director since 2013 Kelvin Womack Director since 2020 Martha G. Aronson Director since 2017 Erik Paulsen Director since 2019 William Cohn, M.D. Director since 2015 Stephen Stenbeck Director since

  11. Slide 11: CSI Today

    CSI Today 2 Manufacturing facilities (St. Paul, Minn. and Pearland, Texas) Serving patients in 31 Countries worldwide 750 Employees 100 Engineers and Scientists Over 300 U.S. Patents and Patents pending

  12. Slide 12: Key Goals

    Key Goals Analyst Day: 2018 Innovation Launch 20 New Products Global Expansion Deliver $25M - $50M in FY23 Grow the Core Business Achieve 10% growth in the core business

  13. Slide 13: Grow and protect the core while we expand into larger markets

    Grow and protect the core while we expand into larger and faster growing markets Focused Transformation Grow and protect Expand global OAS franchises Focused on our complex coronary and peripheral patient population Leveraging the capacity and competency of our U.S. sales channel Innovation to pursu

  14. Slide 14: Grow and Protect

    Highly differentiated and proprietary orbital atherectomy technology Grow and Protect Executing core growth initiatives, improving commercial execution and near-term product pipeline 01 Proven strategy to drive higher revenue per OAS procedure 02 Adoption of OAS internationally remains strong03

  15. Slide 15: Strategy Expands Total Addressable U.S. Markets to $18.8B

    Strategy Expands Total Addressable U.S. Markets to $18.8B Innovation: Pursuing Larger and Faster Growing Markets $18.8B $9.2B TAM HEMODYNAMIC SUPPORT HR-PCI $9.6B $800M TAM PERIPHERAL & CORONARY DCB $8.8B $6.6B TAM THROMBECTOMY PAD & VTE $2.2B PERIPHERAL AND CORONARY OAS AND IVL

  16. Slide 16: Financial Outlook Summary

    Financial Outlook Summary Long-term revenue growth fueled by execution of new platform development into large, high-growth markets 5 Year CAGR of 17% Significant investments in product development and clinical research Attractive and stable gross margins Long-term, sustainable profitability achieved

  17. Slide 17: Today's Agenda

    Today’s Agenda 01 Grow & Protect Global OAS Franchises Scott Ward, Chairman, President & CEO 02 Expanding Product Portfolio Dramatically Increases TAM Matt Cambronne, Vice President, Research & Development 03 Growth Summary & Financial Projections Jeff Points, Chief Financial Officer 04 Closing Comm

  18. Slide 18: CSI Leadership

    CSI Leadership John M. Hastings Executive Vice President, Operations & Technology Robert T. Beverly Vice President & General Manager, Peripheral Sales Harrison T. Boyd II Vice President & General Manager, Coronary Sales Jack E. Nielsen Vice President, Investor Relations & Corporate Communications Je

  19. Slide 19: Grow and Protect Core OAS Business

    Grow and Protect Core OAS Business Scott R. Ward Chairman, President and Chief Executive Officer

  20. Slide 20: Core OAS Business

    US PERIPHERAL US CORONARY INTERNATIONAL Orbital Atherectomy and Interventional Support Devices in the US and International markets Core OAS Business 7% FY22 Revenue: $16.4M OAS: $16.4M OAS Device Sales in: • Japan • Europe • Asia Pacific • Canada • ROW 66% FY22 Revenue: $155.3M OAS: $149.7M ISD: $5.

  21. Slide 21: Leadership in medical evidence

    Leadership in medical evidence Durable patient outcomes Over 83,000 Patients Treated WW in FY22 OAS Has Transformed the Care of Complex Patients Best-in-class professional education Over 700,000 patients Treated with orbital atherectomy since 2007 Innovation Exceptional clinical support

  22. Slide 22: Excellence in Quality and Manufacturing

    Committed to Partnering with our Customers with the Highest Quality Products, Services and Relationships Excellence in Quality and Manufacturing Scalable and continuous COGS reductions (volume and materials costs) to protect OAS margins from ASP declines Manufacturing Initiatives Sourcing and Supply

  23. Slide 23: Customer Service and Relationships are a Core Competitive Advantage

    Customer Service and Relationships are a Core Competitive Advantage US Commercial Sales US Sales Organization Summary 01 02 03 04 05 Deep Clinical Acumen Case Support and Medical Education Long Tenure and Historically Low Turnover Durable Relationships Built on Successful Outcomes Exceptional Sales

  24. Slide 24: Orbital Atherectomy for peripheral & coronary arterial disease

    Orbital Atherectomy for treating peripheral & coronary arterial disease Strong Fundamentals Large, underserved markets High unmet medical need and economic cost OAS is highly differentiated – over 200 patents Partnering with Customers to treat complex cases Robust medical evidence A patient is treat

  25. Slide 25: Unprecedented Evidence in Treating Arterial Calcium

    Unprecedented Evidence in Treating Arterial Calcium Leadership in Medical Evidence Trial Size Importance Peripheral LIBERTY 360° (3-year Data) n=1,204 • “All-comers” trial, any treatment option • Nearly 700 Rutherford Class 4-6 patients enrolled OPTIMIZE (Enrollment Complete) n=66 • OAS + DCB vs. DC

  26. Slide 26: The Diamondback 360 Advantage for Calcified Coronary Artery Disease

    The Diamondback 360® Advantage for Calcified Coronary Artery Disease Robust Medical Evidence: Proven Performance Consistently high rates of procedure success Low rates of procedural complications across large study populations TLR rate of 3.4% at one year in the DES Subset 1. Chambers J, et al. JACC

  27. Slide 27: LIBERTY OAS Sub-analysis

    LIBERTY 360 OAS Sub-analysis (n=503) High Freedom from TVR & Major Amputation at 3 Years 1. CSI Data on File 2. Giannopoulos S, et al. J Endovasc Ther. 2020;27(5):714-725 RC 2-3 RC 4-5 RC 6 RC 2-3 RC 4-5 RC 6 Freedom from TVR/ TLR at 3 Years1 Kaplan-Meier Estimate Freedom from Major Limb Amputation

  28. Slide 28: Evolving to Become a Broad-Based PAD Business

    Evolving to Become a Broad-Based PAD Business Peripheral Executive Summary Innovation and Portfolio Advancement Accelerate Revenue per Procedure • Leveraging ISD portfolio, launching differentiated new products and providing case coverage Restore Growth in Core OAS Drive Market Expansion and OAS ado

  29. Slide 29: Prevent Amputations by Accelerating Patient Access to Care

    Prevent Amputations by Accelerating Patient Access to Care Catalysts for Market Expansion and Growth Market Expansion Broaden Call Points Professional Education • Train 200 new customers per year • Offer advanced procedural training • CLI pathway education • Outcomes and efficiency optimization • Va

  30. Slide 30: Reimbursement Continues to Stabilize

    CMS 2023 proposed rules weighted average impact on CSI procedures increase by 1% Reimbursement Continues to Stabilize AMA CPT Code Restructure (OBL non-facility, Physician) • LER codes are not on September CPT Panel Agenda. Delays push effective date to 2025 or beyond CMS CY2023 Proposed Physician F

  31. Slide 31: Strategy for building high volume OBL accounts

    Strategy for building high volume OBL accounts focused on the care of complex PAD Customized Outpatient Resources – Comprehensive Resources to support high volume OBLs: Pricing Programs Inventory Management Consulting Product Portfolio Claim Assistance Patient Access to Care Clinical Support Profess

  32. Slide 32: Innovation and Portfolio Enhancement

    Full Leg Revascularization Embolic Protection Radial and Pedal Access ATK Mixed Plaque Robust portfolio of options to treat multi-level peripheral disease Innovation and Portfolio Enhancement Exchangeable Series with GlideAssist® Launched 2019 2.0 Max Crown Mixed Plaque Device Launch 2023 Extended L

  33. Slide 33: Full Portfolio of Balloons, Catheters and Guidewires

    Full Portfolio of Balloons, Catheters and Guidewires Leverage scale: 60,000 cases performed in FY22 Accelerate Revenue per Procedure ViperCross™ Support Catheter Zilient® Peripheral Guidewire Launched 2022Launched 2021 Launched 2019 JADE® OTW and Sapphire® 1.0 mm Balloons Shepherd™ Peripheral Guidew

  34. Slide 34: Peripheral Growth Outlook

    Peripheral Growth Outlook ISD Growth Estimate: ~40% Core OAS Growth Estimate: Mid-Single Digits Strive to become a $230M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure OBL Reimbursement 60,000 Patients treated in FY22 Tailwinds Levera

  35. Slide 35: Coronary Executive Summary

    A trusted partner in the treatment of complex coronary artery disease Coronary Executive Summary Restore growth in Core OAS with focus on lesion segmentation Leverage imaging adoption to drive market expansion and vessel preparation with OAS Expansion of medical evidence with ECLIPSE Improve commerc

  36. Slide 36: Lesion Segmentation

    Assuring orbital atherectomy is the treatment of choice for properly selected patients Lesion Segmentation Serving Unique Market Needs Treatment Algorithms Have Formed Balloon Crossable Concentric Short Focal Uniform Single Vessel Uncrossable Eccentric Long Diffuse Nodular Multivessel disease

  37. Slide 37: Imaging: A Catalyst for Market Expansion

    Imaging leads to 28% increase in vessel preparation 1 Imaging: A Catalyst for Market Expansion and Growth Diagnosis Enables physicians to accurately identify calcium and calcium morphology for patient selection and case planning. Increasing Diamondback utilization Assessment Enables physicians and C

  38. Slide 38: Grow and Protect the Coronary Business

    Grow and Protect the Coronary Business Improve Commercial Execution and Focus Reinforce safety data, Versatility, Efficiency and Diamondback Advantage to Capture Cases Leverage Full Portfolio using ISDs, Lesion Targeting, Clinical Acumen and Advanced Techniques to Support Customers Professional educ

  39. Slide 39: Expanding the Coronary Complex Portfolio

    Expanding the Coronary Complex Portfolio Accelerate ISD Growth Teleport® Microcatheter Launched 2022 Launched 2019 Scoreflex® NC Sapphire® NC24 Specialty catheters for chronic total occlusions Launch 2023 Sapphire® ExpansionSapphire® Balloons ViperWire Advance® with Flex Tip Launched 2019 ISD Revenu

  40. Slide 40: Coronary Growth Outlook

    Coronary Growth Outlook ISD Growth Estimate: Mid-20% Core OAS Growth Estimate: Mid-Single Digits Strive to become a $100M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure 14,000 Patients treated in FY22 Tailwinds Leveraging the Full Por

  41. Slide 41: International Executive Summary

    Rapidly increasing scale in International markets International Executive Summary $1.8M $16.4M FY18 FY19 FY20 FY21 FY22 Focused on Established Market Opportunities in Coronary Commercial Execution Through Focused Distribution Network A large, underpenetrated market opportunity for OAS: 4.5 million O

  42. Slide 42: Focused on Coronary in Japan, EU and ROW

    Focused on Coronary in Japan, EU and ROW Commercial Execution Key Drivers Longer Term OpportunitiesGeographic Priorities Invest in high-impact Market Development customized for select target markets Scalability – expand business capabilities/processes & leverage technologies to accelerate growth Pro

  43. Slide 43: International Growth Outlook

    Significant Growth opportunity in International Markets International Growth Outlook Core OAS Growth Estimate: Mid-20% Strive to become a $50M business in FY27 Headwinds COVID Recovery: Staffing and Indirect Supply Chain Vulnerability Competitive Pressure Tailwinds Enter the China Market Emerging Me

  44. Slide 44: Core Business Growth Vectors

    Orbital Atherectomy and Interventional Support Devices in the US and International markets Core Business Growth Vectors US PERIPHERAL FY27: ~$230M US CORONARY FY27: ~$100M INTERNATIONAL FY27: ~$50M OAS Device Sales in: • Japan • Europe • Asia Pacific • Canada • ROW OAS devices: Diamondback, Stealth,

  45. Slide 45: Expanding Product Portfolio Dramatically Increases TAM

    Expanding Product Portfolio Dramatically Increases TAM Matt Cambronne Vice President, Research & Development

  46. Slide 46: Strategy Expands Total Addressable U.S. Markets to $18.8B

    Strategy Expands Total Addressable U.S. Markets to $18.8B Diversification Accelerates Growth $18.8B $9.2B TAM HEMODYNAMIC SUPPORT HR-PCI $9.6B $800M TAM PERIPHERAL & CORONARY DCB $8.8B $6.6B TAM THROMBECTOMY PAD AND VTE $2.2B PERIPHERAL AND CORONARY OAS AND IVL

  47. Slide 47: Product Portfolio Expands into New Segments

    Product Portfolio Expands into New Segments *Prototype products and components are depicted, actual commercial embodiments may vary Product FY22 FY23 FY24 FY25 FY26 FY27 Orbital Atherectomy 2.00 Max Crown OAS Next Generation Coronary Interventional Support Devices Coronary Scoring Balloon CTO Toolki

  48. Slide 48: New Atherectomy & ISD Products

    New Atherectomy & ISD Products OrbusNeich ® Scoreflex ® NC • First non-compliant scoring balloon in the US. Highest rated burst pressure in the US. Intended for in-stent restenosis, mixed plaque, ostial and bifurcated lesions • Initiated launch in Q3 FY22. Commercial performance has exceeded expecta

  49. Slide 49: Thrombectomy

    so MMM, Thrombectomy = >>> ie CARDIOVASCULAR

  50. Slide 50: Venous ThromboEmbolism

    Venous ThromboEmbolism Deep Vein Thrombosis (DVT) Deep Vein Thrombosis (DVT) occurs when a blood clot forms in one or more deep veins, usually in the legs. When a clot formed in deep veins travels to the lungs and blocks the main pulmonary artery or its branches, it causes a Pulmonary Embolism (PE)

  51. Slide 51: US Thrombectomy Market Opportunity

    US Thrombectomy Market Opportunity FY27 FY22 Mechanical Pump-based Aspiration Catheter-directed thrombolysis Mechanical = 20%+ CAGR Mechanical = ~15% CAGR FY22-FY27 Market Size FY27 FY22 Mechanical Pump-based Aspiration Catheter-directed thrombolysis FY22-FY27 Market Size Analyst Estimates, Company

  52. Slide 52: Thrombectomy System Product & Indications

    Application PE, PV PE, PV PE PE Configuration Straight, 45o Curve Straight, 30o Curve Straight, 20o Curve Straight, 10 o Curve Thrombectomy System Product & Indications System consists of a mechanical clot retrieval device and aspiration catheter Initial indication for removal of thrombus from perip

  53. Slide 53: Competitive Advantage

    Competitive Advantage Removed Simulated Soft Clot Aspiration Catheter • Low-profile, navigable design with atraumatic tip • Sizes and curves shapes will address needs across the spectrum of PE and peripheral vascular anatomy Mechanical Retriever • Laser-cut retrieval basket designed for optimizing c

  54. Slide 54: Clinical / Regulatory Strategy

    Clinical / Regulatory Strategy Preliminary Study Designs Indication N Design Endpoints DVT ~130 Single Arm, Prospective, Post- Market Study • Acute Thrombus Removal • Adverse Events/PTS Severity @ 30 days PE ~120 Single Arm, Prospective Multicenter Pivotal Study • Percent reduction in RVLV ratio @ 4

  55. Slide 55: Intravascular Lithotripsy

    M Intravascular Lithotripsy = >>> —FE

  56. Slide 56: Intravascular Lithotripsy

    Intravascular Lithotripsy The technology has since been miniaturized and used in a variety of catheter-based interventions, including treatment of calcified peripheral and coronary arteries High-energy waves including shockwaves have been used in the body for decades for diverse therapeutic uses in

  57. Slide 57: US IVL Market Opportunity

    US IVL Market Opportunity 20%+ CAGR FY27 FY22 ATK/Iliac BTK FY27 FY22 Coronary Coronary IVLPeripheral IVL FY22-FY27 Market SizeFY22-FY27 Market Size 15%+ CAGR ~$215M $600M-700M+ ~$80M PAD (-80% ATK) $150M-200M Total PAD (~75% ATK) Analyst Estimates. Company Estimates

  58. Slide 58: IVL System Balloon Configurations

    IVL System Balloon Configurations Coronary Peripheral ATK/Iliac Peripheral BTK Lengths 12 mm 20 mm 60 mm 40 mm Diameter 2.5 – 4.0 mm 4.0 – 8.0 mm 2.5 – 5.0 mm Guidewire Config RX OTW OTW Product & Indications System consists of a console-based generator, connector and portfolio of catheters Three ba

  59. Slide 59: Competitive Advantage

    Competitive Advantage Electrode test in fluid bath Product design targets • Improved crossing profile • Enhanced deliverability • Wider range of balloon sizes • Greater number of pulses per catheter for more efficient treatment • Simplified system set-up • Improved balloon durability CSI • Large and

  60. Slide 60: IVL Clinical/Regulatory Strategy

    Product FY22 FY23 FY24 FY25 FY26 FY27 Peripheral (ATK/BTK) Coronary IVL Clinical/Regulatory Strategy Preliminary Study Designs Indication N Design Endpoints Peripheral (ATK & BTK) ~120 Multi-center, Prospective Single-arm • Freedom from MAEs at 30 days • Angiographic success (i.e., residual stenosis

  61. Slide 61: Drug Coated Balloons

    M Drug Coated Balloons — >>> —*5

  62. Slide 62: US Drug Coated Balloon Market Opportunity

    US Drug Coated Balloon Market Opportunity FY27 FY22 Peripheral ATK DCB $0M FY27 FY22 Coronary ISR DCB 60%+ CAGR (FY24-FY27) Coronary DCBPeripheral DCB FY22-FY27 Market SizeFY22-FY27 Market Size ~15% CAGR ~$200M $350M-$400M $150M-$200M Analyst Estimates, Company Estimates

  63. Slide 63: Drug Coated Balloons Product & Indications

    Drug Coated Balloons Product & Indications • A portfolio of Everolimus coated balloons intended to treat coronary and peripheral arterial disease • Initial coronary indication will be for the treatment of in-stent restenotic (ISR) lesions • Initial peripheral indication will be for the treatment of

  64. Slide 64: Mechanical Circulatory Support

    Mechanical Circulatory Support

  65. Slide 65: US High Risk PCI Support Market Opportunity

    US High Risk PCI Support Market Opportunity FY27 FY22 High Risk PCI pVAD 15%+ CAGR High Risk PCI Mechanical Circulatory Support FY22-FY27 Market Size United States Coronary Artery Disease1 16.7 Million Annual PCI procedures (excludes CABG) 2 ~1 Million Addressable Market3 400k+ Est. Procedures FY22

  66. Slide 66: Mechanical Circulatory Support (MCS)

    Mechanical Circulatory Support (MCS) Product & Indications • System consists of a disposable micro-axial flow pump catheter and controller, a reusable console, a custom delivery guide wire and a custom introducer kit • Initial indication and use in high-risk PCI procedures to support left ventricula

  67. Slide 67: Focused on Complex Cardiovascular Disease: CSI Product Portfolio

    Focused on Complex Cardiovascular Disease CSI Product Portfolio 2.0 Max Crown - Mixed Plaque Device Vipercath XC, ViperCross & Teleport Catheters WIRION EPD Peripheral IVL Balloons Peripheral Everolimus DCB Thrombectomy: Aspiration Catheters and Clot Retrievers Diamondback & Stealth Diamondback - Ex

  68. Slide 68: Growth Summary & Financial Projections

    Growth Summary & Financial Projections Jeffrey S. Points Chief Financial Officer

  69. Slide 69: Financial Outlook Summary

    Financial Outlook Summary Long-term revenue growth (5 Yr CAGR of 17%) primarily fueled by execution of pipeline products into very large, high-growth markets Attractive gross margins • OAS • ISDs & International • Pipeline Significant investments in product development and clinical research Long-ter

  70. Slide 70: Key Investments Fuel Revenue Growth

    Key Investments Fuel Revenue Growth Investments in growth platforms… 65% 27% 8% FY23 43% 21% 9% 27% FY27 Global Base Business Peripheral Coronary International New Platform Products Revenue Contribution 57% 25% 10% 8% FY25 FY23 FY25 FY27 Revenue $255M - $265M $325M - $350M $500M - $550M CAGR (at mid

  71. Slide 71: Investing In Large, High-Growth Markets

    Investing In Large, High-Growth Markets Targeting large, high growth markets fuels ~17% 5 Yr CAGR $0 $100 $200 $300 $400 $500 $600 FY23 FY25 FY27 High Growth Moderate Growth Lower Growth Drug Coated Balloons Intravascular Lithotripsy Thrombectomy Mechanical Circulatory Support International Atherect

  72. Slide 72: Long Range Outlook: Key Assumptions

    Long Range Outlook: Key Assumptions Outlook Assumes: Inflation normalizes in FY23 Platform product revenues in U.S. only Outlook Does Not Assume: COVID and related impacts A global recession Reimbursement changes New M&A activity

  73. Slide 73: Gross Margin

    Gross Margin TailwindsHeadwinds Impact of inflation on component and freight costs Modest ASP declines Increased mix of lower margin ISDs and International revenue Direct OAS cost reduction programs Increasing volumes New platform products include higher margin profile

  74. Slide 74: Research & Development

    Research & Development Significant investments range from 14% - 17% of revenue TailwindsHeadwinds Investments in clinical trials related to new platform products and geographic markets Higher mechanical circulatory support development costs Outsourcing development costs for new platform products Com

  75. Slide 75: SG&A

    SG&A Incremental leverage drives SG&A spend down to approximately 55% of revenue in FY27 TailwindsHeadwinds Increased costs associated with several major product launches New sales channel for Pulmonary Embolism Thrombectomy product Improved sales rep productivity with new product launches Increased

  76. Slide 76: Capital Allocation

    Capital Allocation Strong balance sheet with no long-term debt Disciplined organization focused on prioritizing and managing spending New platform product transactions begin H2 FY23 Strong banking relationships Current cash position of $160 million provides resources necessary to fund new platform p

  77. Slide 77: Financial Outlook Summary

    Financial Outlook Summary Long-term revenue growth (5 Yr CAGR of 17%) primarily fueled by execution of pipeline products into very large, high-growth markets Attractive gross margins • OAS • ISDs & International • Pipeline Significant investments in product development and clinical research Long-ter

  78. Slide 78: Closing Comments

    Capital Markets Day – August 3, 2022 Closing Comments Scott R. Ward Chairman, President & Chief Executive Officer

  79. Slide 79: Closing summary: leadership, growth and platforms

    79 • Leadership in Atherectomy • Sequential momentum, improving commercial execution & competitiveness • Organic growth & globalization • Rapid growth in ISD sales • New products: 2.0 Max, ScoreFlex and the CTO Toolkit • Core competence in Quality, Manufacturing, R&D and Commercialization • Grow and

  80. Slide 80: Transformation Drives Accelerating Growth

    Transformation Drives Accelerating Growth $- $100 $200 $300 $400 $500 $600 FY22A FY27E New PlatformsInternationalU.S. Coronary FranchiseU.S. Peripheral Franchise $ in millions $500M - $550M CAGR ~17%

  81. Slide 81: Key Investment Merits

    Key Investment Merits Restore revenue growth and deliver key milestones in FY23 Strong sequential growth and momentum in our Core OAS business Improving commercial execution and focus New products: 2.0 Max Crown, ScoreFlex NC and the CTO Toolkit Driving higher revenue per OAS procedure New product p

  82. Slide 82: Meeting the Needs of our Key Stakeholders

    Meeting the Needs of our Key Stakeholders Cardiovascular Systems, Inc. Guided by our Mission Focused on complex peripheral and coronary artery disease Expanding TAM nearly ten-fold with new product platforms Financially strong with the team and talent to win Serving Over 250,000 Patients with $500-$

  83. Slide 83: Q&A Session

    Capital Markets Day – August 3, 2022 Q&A Session CSI Executive Team

  84. Slide 84: Trademarks

    CSI®, Diamondback®, Diamondback 360®, GlideAssist®, Stealth 360®, Take a Stand Against Amputation®, ViperWire®, ViperWire Advance®, Wirion®, Zilient®, Diamondback 360 Precision™, Propel™, Shepherd™, ViperCath™ ViperCross™ and COR™ are trademarks of Cardiovascular Systems, Inc. © 2022 Cardiovascular

Cardiovascular Systems — Investor Day (August 2022) on 6ix